{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T07:32:59Z","timestamp":1780644779914,"version":"3.54.1"},"reference-count":92,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,5,12]],"date-time":"2022-05-12T00:00:00Z","timestamp":1652313600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:p>Hemodialysis (HD) is the most common method of chronic kidney failure (CKF) treatment, with 65% of European patients with CKF receiving HD in 2018. Regular two to three HD sessions weekly severely lower their quality of life, resulting in a higher incidence of depression and anxiety, which is present in one third to one half of these patients. Additionally, the age of patients receiving HD is increasing with better treatment and care, resulting in more cognitive impairment being uncovered. Lastly, patients with other mental health issues can also develop CKF during their life with need for kidney replacement therapy (KRT). All these conditions need to receive adequate care, which often means prescribing psychotropic medications. Importantly, many of these drugs are eliminated through the kidneys, which results in altered pharmacokinetics when patients receive KRT. This narrative review will focus on common issues and medications of CKF patients, their comorbidities, mental health issues, use of psychotropic medications and their altered pharmacokinetics when used in HD, polypharmacy, and drug interactions, as well as deprescribing algorithms developed for these patients.<\/jats:p>","DOI":"10.3389\/fpsyt.2022.882860","type":"journal-article","created":{"date-parts":[[2022,5,12]],"date-time":"2022-05-12T06:36:56Z","timestamp":1652337416000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Polypharmacy and Mental Health Issues in the Senior Hemodialysis Patient"],"prefix":"10.3389","volume":"13","author":[{"given":"Ma\u0161a","family":"Knehtl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadej","family":"Petreski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nejc","family":"Piko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Ekart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastjan","family":"Bevc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,5,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1111\/sdi.12377","article-title":"Management of polypharmacy in dialysis patients.","volume":"28","author":"St Peter","year":"2015","journal-title":"Semin Dial."},{"key":"B2","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1053\/j.ajkd.2019.05.017","article-title":"Cognitive impairment in CKD: pathophysiology, management, and prevention.","volume":"74","author":"Drew","year":"2019","journal-title":"Am J Kidney Dis."},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3390\/pharmacy6030076","article-title":"Polypharmacy and medication-related problems in hemodialysis patients: a call for deprescribing.","volume":"6","author":"Alshamrani","year":"2018","journal-title":"Pharmacy."},{"key":"B4","doi-asserted-by":"crossref","first-page":"57","DOI":"10.18773\/austprescr.2020.004","article-title":"Prescribing in renal supportive care.","volume":"43","author":"Li","year":"2020","journal-title":"Aust Prescr."},{"key":"B5","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1007\/s11920-012-0284-9","article-title":"Clinically significant psychotropic drug-drug interactions in the primary care setting.","volume":"14","author":"English","year":"2012","journal-title":"Curr Psychiatry Rep."},{"key":"B6","doi-asserted-by":"publisher","first-page":"857","DOI":"10.2147\/CIA.S80280","article-title":"Methods to reduce prescribing errors in elderly patients with multimorbidity.","volume":"11","author":"Lavan","year":"2016","journal-title":"Clin Interv Aging."},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-016-1724-8","article-title":"Frequency and clinical relevance of potential cytochrome P450 drug interactions in a psychiatric patient population\u2013an analysis based on German insurance claims data.","volume":"16","author":"Ostermann","year":"2016","journal-title":"BMC Health Serv Res."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1002\/pds.5310","article-title":"Polypharmacy and the risk of drug-drug interactions and potentially inappropriate medications in hospital psychiatry.","volume":"30","author":"Wolff","year":"2021","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B9","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1001\/archgenpsychiatry.2009.175","article-title":"National trends in psychotropic medication polypharmacy in office-based psychiatry.","volume":"67","author":"Mojtabai","year":"2010","journal-title":"Arch Gen Psychiatry."},{"key":"B10","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1080\/14740338.2017.1397128","article-title":"Drug-drug interactions as a result of co-administering \u0394(9)-THC and CBD with other psychotropic agents.","volume":"17","author":"Rong","year":"2018","journal-title":"Expert Opin Drug Saf."},{"key":"B11","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1002\/cpt.1875","article-title":"Chronic inhibition of CYP3A is temporarily reduced by each hemodialysis session in patients with end-stage renal disease.","volume":"108","author":"Egeland","year":"2020","journal-title":"Clin Pharmacol Ther."},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1177\/17539447211058892","article-title":"Leading 20 drug-drug interactions, polypharmacy, and analysis of the nature of risk factors due to QT interval prolonging drug use and potentially inappropriate psychotropic use in elderly psychiatry outpatients.","volume":"15","author":"Das","year":"2021","journal-title":"Ther Adv Cardiovasc Dis."},{"key":"B13","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s00702-020-02291-y","article-title":"Pharmacodynamic drug-drug interactions of QT-prolonging drugs in hospitalized psychiatric patients.","volume":"128","author":"Hefner","year":"2021","journal-title":"J Neural Transm."},{"key":"B14","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.amjopharm.2012.01.001","article-title":"Age-related changes in antidepressant pharmacokinetics and potential drug-drug interactions: a comparison of evidence-based literature and package insert information.","volume":"10","author":"Boyce","year":"2012","journal-title":"Am J Geriatr Pharmacother."},{"key":"B15","first-page":"154","article-title":"Drug-drug-interactions in psychiatry.","volume":"40","author":"Hahn","year":"2013","journal-title":"Psychiatr Prax."},{"key":"B16","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s00115-020-00996-9","article-title":"Antihypertensive drugs in psychiatry : prescription behavior and potential drug-drug interactions.","volume":"92","author":"Endres","year":"2021","journal-title":"Nervenarzt."},{"key":"B17","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s40801-019-0153-5","article-title":"Prevalence of psychotropic polypharmacy and associated healthcare resource utilization during initial phase of care among adults with cancer in USA.","volume":"6","author":"Aroke","year":"2019","journal-title":"Drugs Real World Outcomes."},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/458989","article-title":"Characterization of schizophrenia adverse drug interactions through a network approach and drug classification.","volume":"2013","author":"Sun","year":"2013","journal-title":"Biomed Res Int."},{"key":"B19","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s00213-020-05716-4","article-title":"Drug-drug interactions between COVID-19 treatments and antipsychotics drugs: integrated evidence from 4 databases and a systematic review.","volume":"238","author":"Plasencia-Garc\u00eda","year":"2021","journal-title":"Psychopharmacology."},{"key":"B20","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1517\/17425255.2016.1154043","article-title":"Assessing drug-drug interactions through therapeutic drug monitoring when administering oral second-generation antipsychotics.","volume":"12","author":"Spina","year":"2016","journal-title":"Expert Opin Drug Metab Toxicol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1007\/BF03261907","article-title":"Therapeutic drug monitoring of antidepressants in haemodialysis patients.","volume":"32","author":"Unterecker","year":"2012","journal-title":"Clin Drug Investig."},{"key":"B22","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1097\/FTD.0b013e3181a1c856","article-title":"Therapeutic drug monitoring of clozapine in a hemodialysed smoking patient with schizophrenia.","volume":"31","author":"Jacob","year":"2009","journal-title":"Ther Drug Monit."},{"key":"B23","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1097\/01.ftd.0000168720.19867.43","article-title":"Subtherapeutic risperidone serum concentrations in an adolescent during hemodialysis: a pharmacological puzzle.","volume":"27","author":"Railton","year":"2005","journal-title":"Ther Drug Monit."},{"key":"B24","first-page":"15","article-title":"Geriatric issues in older dialysis patients.","volume":"99","author":"Bhattarai","year":"2016","journal-title":"R I Med J."},{"key":"B25","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1212\/01.wnl.0000225182.15532.40","article-title":"Cognitive impairment in hemodialysis patients is common.","volume":"67","author":"Murray","year":"2006","journal-title":"Neurology."},{"key":"B26","doi-asserted-by":"publisher","first-page":"2511","DOI":"10.1681\/ASN.2016060704","article-title":"Relationship between hypotension and cerebral ischemia during hemodialysis.","volume":"28","author":"MacEwen","year":"2017","journal-title":"J Am Soc Nephrol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1681\/ASN.2017101088","article-title":"Hemodialysis induces an acute decline in cerebral blood flow in elderly patients.","volume":"29","author":"Polinder-Bos","year":"2018","journal-title":"J Am Soc Nephrol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1681\/ASN.2018050462","article-title":"Investigating the relationship between cerebral blood flow and cognitive function in hemodialysis patients.","volume":"30","author":"Findlay","year":"2019","journal-title":"J Am Soc Nephrol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1097\/YIC.0000000000000205","article-title":"Use of antidementia drugs in German patients with Alzheimer\u2019s disease.","volume":"33","author":"Hessmann","year":"2018","journal-title":"Int Clin Psychopharmacol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1007\/s13311-019-00767-8","article-title":"Neuroprotective and antioxidant effect of Ginkgo biloba extract against AD and other neurological disorders.","volume":"16","author":"Singh","year":"2019","journal-title":"Neurotherapeutics."},{"key":"B31","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.trci.2019.07.011","article-title":"Are antidementia drugs associated with reduced mortality after a hospital emergency admission in the population with dementia aged 65 years and older?","volume":"5","author":"Hapca","year":"2019","journal-title":"Alzheimers Dement (N Y)."},{"key":"B32","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1177\/0269881119845795","article-title":"The effect of antidementia drugs on mortality in patients with Alzheimer\u2019s disease.","volume":"33","author":"Lin","year":"2019","journal-title":"J Psychopharmacol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"615","DOI":"10.3233\/JAD-132690","article-title":"Efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer\u2019s disease: a systematic review and meta-analysis.","volume":"41","author":"Tan","year":"2014","journal-title":"J Alzheimers Dis."},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2020.113409","article-title":"Galantamine-memantine combination in the treatment of Alzheimer\u2019s disease and beyond.","volume":"293","author":"Koola","year":"2020","journal-title":"Psychiatry Res."},{"key":"B35","author":"Ashley","year":"2019","journal-title":"The Renal Drug Handbook. The Ultimate Prescribing Guide for Renal Practitioners."},{"key":"B36","article-title":"Donepezil for dementia due to Alzheimer\u2019s disease.","volume":"6","author":"Birks","year":"2018","journal-title":"Cochrane Database Syst Rev."},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-46032-y","article-title":"Nasal delivery of donepezil HCl-loaded hydrogels for the treatment of Alzheimer\u2019s disease.","volume":"9","author":"Al Harthi","year":"2019","journal-title":"Sci Rep."},{"key":"B38","doi-asserted-by":"publisher","first-page":"E1018","DOI":"10.1503\/cmaj.190337","article-title":"Risk of rhabdomyolysis with donepezil compared with rivastigmine or galantamine: a population-based cohort study.","volume":"191","author":"Fleet","year":"2019","journal-title":"CMAJ."},{"key":"B39","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1159\/000351434","article-title":"Effects of different administration protocols on the plasma concentration of donepezil hydrochloride in dementia patients with stage 5 chronic kidney disease.","volume":"3","author":"Amano","year":"2013","journal-title":"Nephron Extra."},{"key":"B40","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1159\/000502682","article-title":"Donepezil treatment for Alzheimer\u2019s disease in chronic dialysis patients.","volume":"9","author":"Yiannopoulou","year":"2019","journal-title":"Case Rep Nephrol Dial."},{"key":"B41","doi-asserted-by":"publisher","first-page":"115","DOI":"10.2174\/157488410791110805","article-title":"A review of clinical pharmacokinetics and pharmacodynamics of galantamine, a reversible acetylcholinesterase inhibitor for the treatment of Alzheimer\u2019s disease, in healthy subjects and patients.","volume":"5","author":"Huang","year":"2010","journal-title":"Curr Clin Pharmacol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"35","DOI":"10.2217\/nmt-2020-0052","article-title":"Evaluation of rivastigmine in Alzheimer\u2019s disease.","volume":"11","author":"Nguyen","year":"2021","journal-title":"Neurodegener Dis Manag."},{"key":"B43","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1254\/jphs.12043fp","article-title":"Effect of renal impairment on the pharmacokinetics of memantine.","volume":"119","author":"Moritoyo","year":"2012","journal-title":"J Pharmacol Sci."},{"key":"B44","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.1111\/jgs.13847","article-title":"Memantine-induced myoclonus precipitated by renal impairment and drug interactions.","volume":"63","author":"Pei","year":"2015","journal-title":"J Am Geriatr Soc."},{"key":"B45","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1097\/JGP.0b013e318186bd7b","article-title":"Memantine dosing in patients with dementia.","volume":"17","author":"Dolder","year":"2009","journal-title":"Am J Geriatr Psychiatry."},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1111\/pcn.12020","article-title":"Memantine-associated renal impairment in a patient with Alzheimer\u2019s disease.","volume":"67","author":"Horikawa","year":"2013","journal-title":"Psychiatry Clin Neurosci."},{"key":"B47","doi-asserted-by":"publisher","first-page":"3736","DOI":"10.1093\/ndt\/gfs295","article-title":"Antidepressants for depression in stage 3-5 chronic kidney disease: a systematic review of pharmacokinetics, efficacy and safety with recommendations by European Renal Best Practice (ERBP).","volume":"27","author":"Nagler","year":"2012","journal-title":"Nephrol Dial Transplant."},{"key":"B48","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1080\/13548506.2018.1469779","article-title":"Quality of life and depression in haemodialysis patients.","volume":"23","author":"Teles","year":"2018","journal-title":"Psychol Health Med."},{"key":"B49","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1080\/17425255.2019.1669560","article-title":"Pharmacokinetic considerations for current state-of-the-art antidepressants.","volume":"15","author":"Wyska","year":"2019","journal-title":"Expert Opin Drug Metab Toxicol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1590\/1516-4446-2018-0264","article-title":"Pharmacokinetics of antidepressants in patients undergoing hemodialysis: a narrative literature review.","volume":"41","author":"Constantino","year":"2019","journal-title":"Braz J Psychiatry."},{"key":"B51","first-page":"121","article-title":"Hemodialyzability of sertraline.","volume":"44","author":"Schwenk","year":"1995","journal-title":"Clin Nephrol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1002\/(sici)1099-1077(199807)13:5<357::aid-hup8>3.0.co;2-k","article-title":"Mirtazapine oral single dose kinetics in patients with different degrees of renal failure.","volume":"13","author":"Bengtsson","year":"1998","journal-title":"Hum Psychopharmacol Clin Exp."},{"key":"B53","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1055\/s-0028-1083822","article-title":"No influence of dialysis on mirtazapine\u2013a case report.","volume":"41","author":"Schlotterbeck","year":"2008","journal-title":"Pharmacopsychiatry."},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2020.108181","article-title":"Antipsychotics circa 2020: what are we thinking?","volume":"175","author":"Remington","year":"2020","journal-title":"Neuropharmacology."},{"key":"B55","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1080\/14740338.2020.1795126","article-title":"Up-to-date expert opinion on the safety of recently developed antipsychotics.","volume":"19","author":"Orsolini","year":"2020","journal-title":"Expert Opin Drug Saf."},{"key":"B56","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1002\/pds.2082","article-title":"Increasing off-label use of antipsychotic medications in the United States, 1995-2008.","volume":"20","author":"Alexander","year":"2011","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B57","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s00127-019-01793-9","article-title":"Oral antipsychotic prescribing and association with neighbourhood-level socioeconomic status: analysis of time trend of routine primary care data in England, 2011-2016.","volume":"55","author":"Buhagiar","year":"2020","journal-title":"Soc Psychiatry Psychiatr Epidemiol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1002\/pds.4244","article-title":"Prescribing trends and indications of antipsychotic medication in Hong Kong from 2004 to 2014: general and vulnerable patient groups.","volume":"26","author":"Lao","year":"2017","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B59","first-page":"592","author":"Ritter","year":"2020","journal-title":"Antipsychotic Drugs. Rang and Dale\u2019s Pharmacology."},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009831.pub2","article-title":"Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders.","volume":"1","author":"Dold","year":"2015","journal-title":"Cochrane Database Syst Rev."},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajp.2020.102484","article-title":"Antipsychotics and hemodialysis: a systematic review.","volume":"55","author":"Sutar","year":"2021","journal-title":"Asian J Psychiatr."},{"key":"B62","first-page":"45","article-title":"Pharmacokinetics of haloperidol in patients on hemodialysis.","volume":"18","author":"Sanga","year":"1998","journal-title":"Nihon Shinkei Seishin Yakurigaku Zasshi."},{"key":"B63","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.2147\/cia.s63942","article-title":"Use of atypical antipsychotics in the elderly: a clinical review.","volume":"9","author":"Gareri","year":"2014","journal-title":"Clin Interv Aging."},{"key":"B64","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1007\/s40262-018-0664-3","article-title":"Clinical pharmacokinetics of atypical antipsychotics: an update.","volume":"57","author":"Mauri","year":"2018","journal-title":"Clin Pharmacokinet."},{"key":"B65","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ajp.2018.02.006","article-title":"Pattern of psychotropic drugs prescription in patients on hemodialysis: a single centre experience from South India.","volume":"31","author":"Uvais","year":"2018","journal-title":"Asian J Psychiatr."},{"key":"B66","doi-asserted-by":"publisher","first-page":"404","DOI":"10.9740\/mhc.2019.11.404","article-title":"Use of therapeutic drug monitoring of risperidone microspheres long-acting injection in hemodialysis: a case report.","volume":"9","author":"Tourtellotte","year":"2019","journal-title":"Ment Health Clin."},{"key":"B67","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1097\/JCP.0000000000001178","article-title":"Serum aripiprazole concentrations prehemodialysis and posthemodialysis in a schizophrenic patient with chronic renal failure: a case report.","volume":"40","author":"De Donatis","year":"2020","journal-title":"J Clin Psychopharmacol."},{"key":"B68","first-page":"169","article-title":"Treatment of a patient with psychotic disorder undergoing haemodialysis: a case report.","author":"Tur\u010din","year":"2018","journal-title":"Psychiatr Danub."},{"key":"B69","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1080\/14740338.2020.1832990","article-title":"A safety evaluation of aripiprazole in the treatment of schizophrenia.","volume":"19","author":"Preda","year":"2020","journal-title":"Expert Opin Drug Saf."},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-200306000-00013","article-title":"Hypothermia in a hemodialysis patient treated with olanzapine monotherapy.","volume":"23","author":"Fukunishi","year":"2003","journal-title":"J Clin Psychopharmacol."},{"key":"B71","first-page":"144","article-title":"Rational deprescribing in the elderly.","volume":"31","author":"Williams","year":"2019","journal-title":"Ann Clin Psychiatry."},{"key":"B72","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1111\/ijpp.12674","article-title":"Issues with deprescribing in haemodialysis: a qualitative study of patient and provider experiences.","volume":"28","author":"Bondurant-David","year":"2020","journal-title":"Int J Pharm Pract."},{"key":"B73","doi-asserted-by":"publisher","first-page":"144","DOI":"10.2215\/CJN.05270420","article-title":"Addressing polypharmacy in outpatient dialysis units.","volume":"16","author":"Battistella","year":"2020","journal-title":"Clin J Am Soc Nephrol."},{"key":"B74","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/j.mcna.2020.06.001","article-title":"Thoughtful prescribing and deprescribing.","volume":"104","author":"Pravodelov","year":"2020","journal-title":"Med Clin North Am."},{"key":"B75","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1016\/0895-4356(92)90144-c","article-title":"A method for assessing drug therapy appropriateness.","volume":"45","author":"Hanlon","year":"1992","journal-title":"J Clin Epidemiol."},{"key":"B76","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1001\/jama.2017.5706","article-title":"Management of depression in older adults: a review.","volume":"317","author":"Kok","year":"2017","journal-title":"JAMA."},{"key":"B77","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1093\/ageing\/afu145","article-title":"STOPP\/START criteria for potentially inappropriate prescribing in older people: version 2.","volume":"44","author":"O\u2019Mahony","year":"2015","journal-title":"Age Ageing."},{"key":"B78","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1080\/17512433.2020.1697676","article-title":"STOPP\/START criteria for potentially inappropriate medications\/potential prescribing omissions in older people: origin and progress.","volume":"13","author":"O\u2019Mahony","year":"2020","journal-title":"Expert Rev Clin Pharmacol."},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n1585","article-title":"ptimizing therapy to prevent avoidable hospital admissions in multimorbid older adults (OPERAM): cluster randomised controlled trial.","volume":"374","author":"Blum","year":"2021","journal-title":"BMJ."},{"key":"B80","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1093\/ageing\/afaa072","article-title":"Prevention of adverse drug reactions in hospitalized older patients with multi-morbidity and polypharmacy: the SENATOR* randomized controlled clinical trial.","volume":"49","author":"O\u2019Mahony","year":"2020","journal-title":"Age Ageing."},{"key":"B81","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1007\/s41999-020-00378-z","article-title":"FORTA(Fit-fOR-The-Aged)-based medication optimization: retrospective analysis of experiences from an unconventional outpatient service.","volume":"11","author":"Rieg","year":"2020","journal-title":"Eur Geriatr Med."},{"key":"B82","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1111\/jgs.15767","article-title":"American geriatrics society 2019 updated AGS beers criteria(R) for potentially inappropriate medication use in older adults.","volume":"67","year":"2019","journal-title":"J Am Geriatr Soc."},{"key":"B83","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1111\/jcpt.12494","article-title":"The use of potentially inappropriate medications among the Lithuanian elderly according to Beers and EU(7)-PIM list\u2013a nationwide cross-sectional study on reimbursement claims data.","volume":"42","author":"Grina","year":"2017","journal-title":"J Clin Pharm Ther."},{"key":"B84","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1590\/1806-9282.66.7.918","article-title":"Beers AGS 2019 criteria in very old hospitalized patients.","volume":"2020","author":"Gorzoni","year":"1992","journal-title":"Rev Assoc Med Bras."},{"key":"B85","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1007\/s00228-015-1860-9","article-title":"The EU(7)-PIM list: a list of potentially inappropriate medications for older people consented by experts from seven European countries.","volume":"71","author":"Renom-Guiteras","year":"2015","journal-title":"Eur J Clin Pharmacol."},{"key":"B86","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1007\/s40266-018-0593-8","article-title":"The role of deprescribing in older adults with chronic kidney disease.","volume":"35","author":"Triantafylidis","year":"2018","journal-title":"Drugs Aging."},{"key":"B87","doi-asserted-by":"publisher","first-page":"3323","DOI":"10.1007\/s11606-020-06089-2","article-title":"Deprescribing for community-dwelling older adults: a systematic review and meta-analysis.","volume":"35","author":"Bloomfield","year":"2020","journal-title":"J Gen Intern Med."},{"key":"B88","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1111\/nep.13936","article-title":"Active deprescribing program in chronic kidney disease patients undergoing haemodialysis.","volume":"26","author":"George","year":"2021","journal-title":"Nephrology."},{"key":"B89","doi-asserted-by":"publisher","first-page":"174","DOI":"10.5694\/mja2.50015","article-title":"Deprescribing cholinesterase inhibitors and memantine in dementia: guideline summary.","volume":"210","author":"Reeve","year":"2019","journal-title":"Med J Aust."},{"key":"B90","first-page":"339","article-title":"Deprescribing benzodiazepine receptor agonists: Evidence-based clinical practice guideline.","volume":"64","author":"Pottie","year":"2018","journal-title":"Can Fam Physician."},{"key":"B91","first-page":"17","article-title":"Deprescribing antipsychotics for behavioural and psychological symptoms of dementia and insomnia: evidence-based clinical practice guideline.","volume":"64","author":"Bjerre","year":"2018","journal-title":"Can Fam Physician."},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1177\/2054358120968674","article-title":"Development and validation of nine deprescribing algorithms for patients on hemodialysis to decrease polypharmacy.","volume":"7","author":"Lefebvre","year":"2020","journal-title":"Can J Kidney Health Dis."}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2022.882860\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,12]],"date-time":"2022-05-12T06:37:13Z","timestamp":1652337433000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2022.882860\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,12]]},"references-count":92,"alternative-id":["10.3389\/fpsyt.2022.882860"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2022.882860","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,12]]},"article-number":"882860"}}